ELAN Elanco Animal Health Inc Insider Trading

Modi Rajeev A. bought 4,911 shares of ELAN at $20.35 on 2026-05-15; stock now down -28.6% from 52-week high.

Modi Rajeev A. purchased 4,911 shares at $20.35 on 2026-05-15, increasing holdings by 3.2% to 160,812 shares post-transaction. The transaction occurs as ELAN trades at $19.80, down -16.4% over 30 days and down -28.6% from its 52-week high of $27.72. While Modi's prior buy at this ticker (2025-12-11) produced positive 90-day returns and was well-timed, the current price action presents a contrasting backdrop. The company generated $1,371,000,000 in latest quarterly revenue with a market cap of $9,889,101,743.40, though it reported negative full-year net income despite posting $57,000,000 in quarterly net income. The timing of this purchase against the stock's recent downward trajectory and the company's broader profitability challenges merit investor attention.

CEO Simmons buys 4,971 shares of ELAN at $20.08; stock down -28.6% from 52-week high

CEO and President Jeffrey N Simmons purchased 4,971 shares at $20.08 on 2026-05-15, increasing his holdings to 171,971 shares. The purchase occurs against a backdrop of material price weakness: the stock trades at $19.80, down -28.6% from its 52-week high of $27.72 and down -16.4% over the prior 30 days. Fundamentals show the company generated $1,371,000,000 in quarterly revenue with annual revenue growth of 6.2%, though the company was unprofitable over its most recent full fiscal year. The timing of this insider purchase during a period of elevated price pressure warrants attention, particularly given the stock's cumulative decline across multiple timeframes.

Director Kurzius Erik purchases 10,000 shares of ELAN at $21.30; cluster of 4 insiders buying within 14 days as stock rallies 22.0% in 90 days

Kurzius Lawrence Erik, a Director at Elanco Animal Health, purchased 10,000 shares at $21.30 on 2025-12-12, increasing his holdings to 131,773 shares. This transaction is part of a cluster buy pattern, with 3 other insiders also purchasing shares within the past 14 days. Kurzius's prior trades at ELAN show a strong timing pattern: both prior buys (on 2025-03-11 and 2025-03-07) delivered positive 90-day returns of +36.5% and +23.2% respectively. The current environment is favorable—ELAN has rallied 22.0% over 90 days and 6.6% over 30 days, and is trading near its 52-week high at $22.49 versus a 52-week range of $8.10–$23.43. However, the company's fundamentals remain challenged: net income is -$34.0M on $1.1B quarterly revenue, with minimal annual revenue growth of +0.5% and a P/E ratio of 321.29, reflecting an unprofitable or extremely low-margin business. The cluster buying signal and Kurzius's historical buying track record at this ticker warrant investor attention to whether insiders perceive value or upcoming catalysts not yet reflected in public data.

CFO Robert VanHimbergen buys 6,950 shares of ELAN at $21.64; cluster of 3 other insiders bought within 14 days; stock down 7.4% from 52-week high

CFO VanHimbergen acquired 6,950 shares at $21.64, increasing his position from 117,283 to 124,233 shares. The transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated internal confidence amid broader context. However, context is mixed: ELAN trades at P/E of 310.00 with negative net income of $-34,000,000, annual revenue growth of only +0.5%, and the stock sits 7.4% below its 52-week high. VanHimbergen's cross-ticker track record shows an underwhelming 25.00% win rate over 90 days with average 90d return of -4.9%, meaning his past open-market buys have historically faced headwinds. The purchase near current price of $21.70 occurs in a fundamentally challenged environment.

Modi Rajeev A. purchases 4,500 shares of ELAN at $21.33; cluster pattern with 3 other insiders buying within 14 days

Modi Rajeev A. purchased 4,500 shares at $21.33, bringing holdings to 123,082 shares—a +3.8% increase versus pre-transaction holdings. The transaction occurs alongside a cluster pattern: 3 other insiders also bought within the past 14 days, indicating coordinated insider accumulation at the same price level. The stock trades at $21.70 currently, only −7.4% from its 52-week high of $23.43, though the company reports a negative net income of $−34.0M against revenue of $1.1B, with an elevated P/E of 310.00 reflecting subdued earnings. The 90-day price momentum of +16.5% and 30-day gain of +2.9% show recent strength despite fundamental headwinds. Synchronized insider purchases during a recovery phase warrant investor attention to whether management perceives improved near-term prospects.

Elanco CEO Simmons buys 22,000 shares for $478.5K; cluster of 3 other insiders also bought in past 14 days.

On 2025-12-11, Simmons Jeffrey N (PRESIDENT, CEO AND DIRECTOR) purchased 22,000 shares of Elanco Animal Health Inc (ELAN) at $21.75, increasing his holdings from 145,000 to 167,000 shares. The transaction occurred amid a cluster of 3 other insider purchases within the past 14 days, suggesting coordinated confidence at current levels. Elanco is trading at $21.70 (near the transaction price), down 7.4% from its 52-week high of $23.43, and has posted a 90-day return of +16.5%. The company faces headwinds: net income is currently negative at $-34.0M on revenue of $1.1B, with minimal annual growth of +0.5% and a stretched P/E of 310.00, reflecting an unprofitable near-term picture.

Elanco director Kurzius purchased 20,000 shares for $211,000.00 across two trades; stock down 45.6% from 52-week high.

Kurzius Lawrence Erik, a director at Elanco Animal Health Inc (ELAN), made two separate open-market purchases totaling 20,000 shares for $211,000.00 in early March 2025, with a blended average price of $10.55. His holdings increased 21.9% from 91,459 to 111,459 shares. The timing of these purchases is notable: ELAN's stock is currently priced at $10.04, approximately 45.6% below its 52-week high of $18.45, and down 19.9% over the last 90 days. The company reports strong fundamentals with $1.0B in quarterly revenue and a notably low P/E of 2.80. However, the director's cross-ticker track record shows modest performance with a 90-day well-timed sale rate of 33.33%, suggesting his prior market timing has been mixed. The substantial markdown from the 52-week high warrants attention to whether this accumulation reflects opportunistic positioning in a depressed market or other considerations.

ELAN Director Hoover buys 25,000 shares at $10.90; 90-day prior buy returned +12.8%

Hoover R David, a Director of Elanco Animal Health Inc (ELAN), purchased 25,000 shares at $10.90 on 2025-03-05, expanding his holdings by 13.5% from 185,000 to 210,000 shares. This represents a $272,557.50 investment in an environment where ELAN trades at $11.14 (near the bottom of its 52-week range of $10.70–$18.45, down 39.6% from the 52-week high). His prior open-market purchase at ELAN on 2024-03-06 delivered a 90-day return of +12.8%, and his cross-ticker track record shows a 100.00% 90-day win rate with an average 90-day return of +12.8%. The stock has declined 7.4% over 30 days and 10.9% over 90 days from prior price levels, signaling a period of weakness. The company's fundamentals show a P/E of 3.10 and net income of $364,000,000.00 against revenue of $1,030,000,000.00, though annual revenue growth is minimal at +0.5%.

Director Michael J Harrington bought 3,500 shares of ELAN at $14.85 on 2024-08-22; stock down 21.4% from 52-week high despite +12.4% 30-day bounce.

Director Harrington purchased 3,500 shares at $14.85, increasing his holdings to 81,094 shares (+4.5% position growth). The timing of this purchase follows a 12.4% 30-day rally in ELAN, though the stock remains 21.4% below its 52-week high of $18.45. Fundamentally, the company is unprofitable with net income of $-50,000,000 and minimal revenue growth of +0.1%, representing a challenged operational backdrop. Looking at his same-ticker history, Harrington's prior purchase at ELAN on 2024-03-08 posted a +12.2% 90-day return, establishing a pattern of favorable post-purchase outcomes at this ticker, though this is limited to a single prior trade.

CEO Simmons purchases 100,000 shares of ELAN at $13.01; holdings triple to 145,000 amid unprofitability

CEO Jeffrey Simmons purchased 100,000 shares (100.0K shares) at $13.01, tripling his holdings from 45,000 shares (45.0K shares) to 145,000 shares (145.0K shares). This substantial open-market accumulation by the top executive occurs while Elanco faces material headwinds: the company posted a net loss of $-50,000,000 ($-50.0M) in its most recent fiscal year and reported negative net income in the latest quarter, with annual revenue growth stalled at +0.1%. The stock has declined 24.4% from its 52-week high of $18.45 and is down 18.2% over the past 90 days, trading at $13.94 today—just $0.93 above the transaction price. A CEO acquiring shares of this magnitude during a period of operating losses and negative momentum warrants investor attention to the company's operational trajectory and management's internal view of recovery prospects.